SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
This Quarter Return
+4.89%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$5.16B
AUM Growth
+$5.16B
(-12%)
Cap. Flow
-$795M
Cap. Flow
% of AUM
-15.4%
Top 10 Holdings %
Top 10 Hldgs %
43.21%
Holding
125
New
19
Increased
28
Reduced
23
Closed
30
Top Buys
| 1 |
Microsoft
MSFT
|
$291M |
| 2 |
Monster Beverage
MNST
|
$110M |
| 3 |
Hilton Worldwide
HLT
|
$93.4M |
| 4 |
Marriott International Class A Common Stock
MAR
|
$81.6M |
| 5 |
Deckers Outdoor
DECK
|
$79.2M |
Top Sells
| 1 |
Twilio
TWLO
|
$165M |
| 2 |
Mastercard
MA
|
$152M |
| 3 |
Adobe
ADBE
|
$137M |
| 4 |
PLAN
Anaplan, Inc.
PLAN
|
$132M |
| 5 |
UnitedHealth
UNH
|
$130M |
Sector Composition
| 1 | Healthcare | 35.27% |
| 2 | Consumer Discretionary | 21.54% |
| 3 | Technology | 17.68% |
| 4 | Industrials | 15.65% |
| 5 | Consumer Staples | 5.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KDNY
51
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $20.3M | 0.39% |
1,247,468
+200,000
| +19% | +$3.26M |
|
52
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $19.5M | 0.38% |
1,218,792
+729,459
| +149% | +$11.6M |
|
|
CMRX
53
DELISTED
Chimerix, Inc.
CMRX
| $17.8M | 0.34% |
2,766,619
+858,999
| +45% | +$5.52M |
|
54
InflaRx
IFRX
$108M
| $15.6M | 0.3% |
3,285,000
| – | – |
|
|
PNT
55
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $15M | 0.29% |
2,672,863
+447,863
| +20% | +$2.51M |
|
|
MREO
56
Mereo BioPharma
MREO
$272M
| $14.6M | 0.28% |
9,142,067
| – | – |
|
57
Grab
GRAB
$20.3B
| $14.3M | 0.28% |
+2,000,000
| New | +$14.3M |
|
58
Spyre Therapeutics
SYRE
$996M
| $12.2M | 0.24% |
2,571,000
+413,273
| +19% | +$1.96M |
|
59
Pharvaris
PHVS
$1.39B
| $11.9M | 0.23% |
+827,540
| New | +$11.9M |
|
60
Solid Biosciences
SLDB
$427M
| $11M | 0.21% |
6,287,193
+313,000
| +5% | +$548K |
|
61
Bolt Biotherapeutics
BOLT
$9.85M
| $10.9M | 0.21% |
2,230,250
+904,750
| +68% | +$4.43M |
|
|
DICE
62
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $10.4M | 0.2% |
410,000
| – | – |
|
|
AMAM
63
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $9.55M | 0.18% |
+1,057,735
| New | +$9.55M |
|
64
Terns Pharmaceuticals
TERN
$609M
| $8.76M | 0.17% |
1,238,800
+113,064
| +10% | +$799K |
|
|
MOLN
65
Molecular Partners
MOLN
$140M
| $7.67M | 0.15% |
400,000
| – | – |
|
|
SIOX
66
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $7.63M | 0.15% |
5,914,000
+425,000
| +8% | +$548K |
|
|
INZY
67
DELISTED
Inozyme Pharma
INZY
| $6.91M | 0.13% |
1,013,216
+26,816
| +3% | +$183K |
|
68
Disc Medicine
IRON
$2.07B
| $6.9M | 0.13% |
2,372,267
+234,444
| +11% | +$682K |
|
69
Roivant Sciences
ROIV
$8.15B
| $6.87M | 0.13% |
+681,528
| New | +$6.87M |
|
70
Oric Pharmaceuticals
ORIC
$994M
| $6.48M | 0.13% |
440,696
+291,596
| +196% | +$4.29M |
|
71
Milestone Pharmaceuticals
MIST
$156M
| $5.58M | 0.11% |
851,291
| – | – |
|
|
OTIC
72
DELISTED
Otonomy, Inc.
OTIC
| $5.57M | 0.11% |
2,678,115
+290,415
| +12% | +$604K |
|
|
RACB
73
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $4.89M | 0.09% |
500,000
| – | – |
|
74
Allogene Therapeutics
ALLO
$251M
| $3.96M | 0.08% |
+265,116
| New | +$3.96M |
|
75
Nuvalent
NUVL
$5.52B
| $3.81M | 0.07% |
200,000
| – | – |
|